VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

CEO

Mr. Jeffery R. Baxter FCMA

Pekerja

131

Negara

Kanada

ISIN

CA91822J1030

Penyenaraian

STU

LO91.STU

0 Comments

Kongsi pendapat anda

FAQ

Apakah simbol saham VBI Vaccines?▼

Bergantung pada bursa, simbol saham mungkin berbeza. Sebagai contoh, di bursa Boerse Stuttgart, saham VBI Vaccines didagangkan di bawah simbol LO91.STU.

Adakah VBI Vaccines membayar dividen?▼

Ya, dividen LO91.STU dibayar tahunan. Dividen terakhir bagi setiap saham ialah 17.02 EUR. Setakat hari ini, Hasil Dividen (FWD)% ialah 0%.

Berapa ramai pekerja yang dimiliki oleh VBI Vaccines?▼

Sehingga Julai 25, 2026, syarikat mempunyai 131 pekerja.

VBI Vaccines terletak dalam sektor apa?▼

VBI Vaccines beroperasi dalam sektor Kesihatan & Kesejahteraan.

Bilakah VBI Vaccines menyiapkan split saham?▼

Pecahan saham terakhir bagi VBI Vaccines berlaku pada April 12, 2023 dengan nisbah 1:30.

Di manakah ibu pejabat VBI Vaccines?▼

Ibu pejabat VBI Vaccines terletak di Cambridge, Kanada.